| 1 |
马丽媛，吴亚哲，陈伟伟.《中国心血管病报告2018》要点介绍[J]. 中华高血压杂志, 2019, 27(8):712-716.
|
| 2 |
刘丹，何涛. 缺血性心力衰竭的非药物治疗进展[J]. 山东医药, 2018, 58(33):91-93.
|
| 3 |
曲泽澎，贾兆锋，黄曦, 等. 间充质干细胞在器官移植中的应用研究进展[J]. 器官移植, 2018, 9(5):348-353.
|
| 4 |
Wang M, Hu R, Yang Y, et al. In vivo ultrasound molecular imaging of SDF-1 expression in a swine model of acute myocardial infarction[J/OL]. Front Pharmacol, 2019, 10:899.
|
| 5 |
Bareja A, Patel S, Hodgkinson CP, et al. Understanding the mechanism of bias signaling of the insulin-like growth factor 1 receptor: Effects of LL37 and HASF[J]. Cell Signal, 2018, 46:113-119.
|
| 6 |
Datta R, Bansal T, Rana S, et al. Myocyte-derived Hsp90 modulates collagen upregulation via biphasic activation of STAT-3 in fibroblasts during cardiac hypertrophy[J/OL]. Mol cell Biol, 2017, 37(6):e00611-16.
|
| 7 |
Ibrahim AG, Cheng K, Marbán E. Exosomes as critical agents of cardiac regeneration triggered by cell therapy[J]. Stem Cell Reports, 2014, 2(5):606-619.
|
| 8 |
Xiao J, Pan Y, Li XH, et al. Cardiac progenitor cell-derived exosomes prevent cardiomyocytes apoptosis through exosomal miR-21 by targeting PDCD4[J/OL]. Cell death dis, 2016, 7(6):e2277.
|
| 9 |
Nguyen PK, Neofytou E, Rhee JW, et al. Potential strategies to address the major clinical barriers facing stem cell regenerative therapy for cardiovascular disease: a review[J]. JAMA Cardiol, 2016, 1(8):953-962.
|
| 10 |
Khan M, Nickoloff E, Abramova T, et al. Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction[J]. Circ Res, 2015, 117(1):52-64.
|
| 11 |
Liu B, Lee BW, Nakanishi K, et al. Cardiac recovery via extended cell-free delivery of extracellular vesicles secreted by cardiomyocytes derived from induced pluripotent stem cells[J]. Nat Biomed Eng, 2018, 2(5):293-303.
|
| 12 |
Menasché P, Vanneaux V, Hagège A, et al. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report[J]. Eur Heart J, 2015, 36(30):2011-2017.
|
| 13 |
Menasché P, Vanneaux V, Hagege A, et al. Transplantation of human embryonic stem cell-derived cardiovascular progenitors for severe ischemic left ventricular dysfunction[J]. J Am Coll Cardiol, 2018, 71(4):429-438.
|
| 14 |
Silva Dos Santos D, Brasil GV, Ramos IPR, et al. Embryonic stem cell-derived cardiomyocytes for the treatment of doxorubicin-induced cardiomyopathy[J/OL]. Stem Cell Res Ther, 2018, 9(1):30.
|
| 15 |
Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors[J]. Cell, 2006, 126(4):663-676.
|
| 16 |
Sun X, Nunes SS. Bioengineering approaches to mature human pluripotent stem cell-derived cardiomyocytes[J/OL]. Front Cell Dev Biol, 2017, 5:19.
|
| 17 |
Gao L, Gregorich ZR, Zhu W, et al. Large cardiac muscle patches engineered from human induced-pluripotent stem cell-derived cardiac cells improve recovery from myocardial infarction in Swine[J]. Circulation, 2018, 137(16):1712-1730.
|
| 18 |
Streckfuss-Bömeke K, Tiburcy M, Fomin A, et al. Severe DCM phenotype of patient harboring RBM20 mutation S635A can be modeled by patient-specific induced pluripotent stem cell-derived cardiomyocytes[J]. J Mol Cell Cardiol, 2017, 113:9-21.
|
| 19 |
Tang XL, Li Q, Rokosh G, et al. Long-Term Outcome of Administration of c-kit(POS) Cardiac Progenitor Cells After Acute Myocardial Infarction: Transplanted Cells Do not Become Cardiomyocytes, but Structural and Functional Improvement and Proliferation of Endogenous Cells Persist for at Least One Year[J]. Circ Res, 2016, 118(7):1091-1105.
|
| 20 |
Ishigami S, Ohtsuki S, Tarui S, et al. Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the TICAP prospective phase 1 controlled trial[J]. Circ Res, 2015, 116(4):653-664.
|
| 21 |
Ishigami S, Ohtsuki S, Eitoku T, et al. Intracoronary cardiac progenitor cells in single ventricle physiology: The PERSEUS (Cardiac Progenitor cell infusion to treat univentricular heart disease) randomized phase 2 trial[J]. Circ Res, 2017, 120(7):1162-1173.
|
| 22 |
Bittle GJ, Morales D, Deatrick KB, et al. Stem cell therapy for hypoplastic left heart syndrome: Mechanism, clinical application, and future directions[J]. Circ Res, 2018, 123(2):288-300.
|
| 23 |
Hare JM, DiFede DL, Rieger AC, et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial[J]. J Am Coll Cardiol, 2017, 69(5):526-537.
|
| 24 |
Premer C, Wanschel A, Porras V, et al. Mesenchymal stem cell secretion of sdf-1alpha modulates endothelial function in dilated cardiomyopathy[J/OL]. Front Physiol, 2019, 10:1182.
|
| 25 |
Fontaine MJ, Shih H, Schafer R, et al. Unraveling the mesenchymal stromal cells' paracrine immunomodulatory effects[J]. Transfus Med Rev, 2016, 30(1):37-43.
|
| 26 |
Epstein SE, Luger D, Lipinski MJ. Paracrine-mediated systemic anti-inflammatory activity of intravenously administered mesenchymal stem cells: A transformative strategy for cardiac stem cell therapeutics[J]. Circ Res, 2017, 121(9):1044-1046.
|
| 27 |
Luger D, Lipinski MJ, Westman PC, et al. Intravenously delivered mesenchymal stem cells: systemic anti-inflammatory effects improve left ventricular dysfunction in acute myocardial infarction and ischemic cardiomyopathy[J]. Circ Res, 2017, 120(10):1598-1613.
|
| 28 |
Butler J, Epstein SE, Greene SJ, et al. Intravenous allogeneic mesenchymal stem cells for nonischemic cardiomyopathy: Safety and efficacy results of a phase II-A randomized trial[J]. Circ Res, 2017, 120(2):332-340.
|
| 29 |
Teng X, Chen L, Chen W, et al. Mesenchymal stem cell-derived exosomes improve the microenvironment of infarcted myocardium contributing to angiogenesis and anti-inflammation[J]. Cell Physiol Biochem, 2015, 37(6):2415-2424.
|
| 30 |
Bellin G, Gardin C, Ferroni L, et al. Exosome in cardiovascular diseases: a complex world full of hope[J/OL]. Cells, 2019, 8(2):166.
|
| 31 |
de Couto G, Gallet R, Cambier L, et al. Exosomal microrna transfer into macrophages mediates cellular postconditioning[J]. Circulation, 2017, 136(2):200-214.
|
| 32 |
Wang K, Jiang Z, Webster KA, et al. Enhanced cardioprotection by human endometrium mesenchymal stem cells driven by exosomal MicroRNA-21[J]. Stem Cells Transl Med, 2017, 6(1):209-222.
|
| 33 |
Zhang CS, Shao K, Liu CW, et al. Hypoxic preconditioning BMSCs-exosomes inhibit cardiomyocyte apoptosis after acute myocardial infarction by upregulating microRNA-24[J]. Eur Rev Med Pharmacol Sci, 2019, 23(15):6691-6699.
|
| 34 |
张海涛，林文勇，解曼曼, 等. 冠心病患者外周血外泌体中microRNA基因芯片的差异性表达[J]. 临床心血管病杂志, 2019, 35(6):501-505.
|
| 35 |
Watson DC, Bayik D, Srivatsan A, et al. Efficient production and enhanced tumor delivery of engineered extracellular vesicles[J]. Biomaterials, 2016, 105:195-205.
|
| 36 |
Vandergriff A, Huang K, Shen D, et al. Targeting regenerative exosomes to myocardial infarction using cardiac homing peptide[J]. Theranostics, 2018, 8(7):1869-1878.
|
| 37 |
Zhu LP, Tian T, Wang JY, et al. Hypoxia-elicited mesenchymal stem cell-derived exosomes facilitates cardiac repair through miR-125b-mediated prevention of cell death in myocardial infarction[J]. Theranostics, 2018, 8(22):6163-6177.
|
| 38 |
Tang J, Su T, Huang K, et al. Targeted repair of heart injury by stem cells fused with platelet nanovesicles[J]. Nat Biomed Eng, 2018, 2:17-26.
|
| 39 |
Ma J, Zhao Y, Sun L, et al. Exosomes derived from akt-modified human umbilical cord mesenchymal stem cells improve cardiac regeneration and promote angiogenesis via activating platelet-derived growth factor D[J]. Stem Cells Transl Med, 2017, 6(1):51-59.
|
| 40 |
Cho HM, Lee KH, Shen YM, et al. Transplantation of hMSCs genome edited with LEF1 improves cardio-protective effects in myocardial infarction[J]. Mol Ther Nucleic Acids, 2020, 19:1186-1197.
|
| 41 |
刘志江，束波，石蓓, 等. HMGB1预处理骨髓间充质干细胞移植治疗心肌梗死大鼠的实验研究[J]. 临床心血管病杂志, 2017, 33(7):683-687.
|
| 42 |
Muller P, Lemcke H, David R. Stem cell therapy in heart diseases-cell types, mechanisms and improvement strategies[J]. Cell Physiol Biochem, 2018, 48(6): 2607-2655.
|